Cargando…

Effect of iloprost on biomarkers in patients with congenital heart disease‐pulmonary arterial hypertension

Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension (PAH), including nitric oxide (NO), endothelin‐1 (ET‐1), asymmetric dimethylarginine (ADMA), galectin‐3 (Gal‐3), B‐type natriuretic peptide (BNP), and uric acid (UA). However, studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiao‐ye, Zheng, Yu, Long, Yuliang, Zhang, Xiaochun, Zhang, Lei, Tian, Dan, Zhou, Daxin, Lv, Qian‐zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601287/ https://www.ncbi.nlm.nih.gov/pubmed/28608969 http://dx.doi.org/10.1111/1440-1681.12796

Ejemplares similares

Review of inhaled iloprost for the control of pulmonary artery hypertension in children
por: Tissot, Cecile, et al.
Publicado: (2009)

Inhaled iloprost for the control of pulmonary hypertension
por: Krug, Sabine, et al.
Publicado: (2009)

Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension
por: Hwang, Seung-Kyung, et al.
Publicado: (2009)

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension
por: Fernandes, Caio J.C.S., et al.
Publicado: (2021)

Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure
por: Martischnig, Amadea M., et al.
Publicado: (2011)

Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography
por: Loureiro, Maria José, et al.
Publicado: (2007)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Acute Iloprost Inhalation Improves Right Ventricle Function in Pulmonary Artery Hypertension: A Cardiac Magnetic Resonance Study
por: Li, Jing-Hui, et al.
Publicado: (2019)

Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates
por: Tavares‐Silva, Marta, et al.
Publicado: (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2018)

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension
por: Gessler, Tobias, et al.
Publicado: (2017)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
por: Yıldırım, Şükran
Publicado: (2023)

Efficacy of inhaled iloprost in the management of pulmonary hypertension after cardiopulmonary bypass in infants undergoing congenital heart surgery. A case series of 31 patients
por: Müller, M, et al.
Publicado: (2011)

Iloprost in pulmonary hypertension due to sub-massive pulmonary embolism: report of two cases
por: Alsaghir, Abdullah Hassan, et al.
Publicado: (2013)

The use of iloprost in the treatment of ‘out of proportion’ pulmonary hypertension in chronic obstructive pulmonary disease
por: Lasota, Bartosz, et al.
Publicado: (2013)

Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
por: Jain, Pritesh P, et al.
Publicado: (2014)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension
por: Wang, Lan, et al.
Publicado: (2017)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study
por: Richter, Manuel J., et al.
Publicado: (2019)

Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP)
por: Stollfuss, Barbara, et al.
Publicado: (2021)

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs
por: Jin, Qi, et al.
Publicado: (2023)

Long‐term prognostic value of cardiac catheterization and acute vasodilator testing with inhaled iloprost in pediatric idiopathic pulmonary arterial hypertension
por: Zhang, Chen, et al.
Publicado: (2022)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Inhaled iloprost induces long‐term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy
por: Yasuda, Kenichiro, et al.
Publicado: (2022)

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

Effects of inhaled iloprost on right ventriculovascular coupling and ventricular interdependence in acute pulmonary hypertension
por: Rex, S, et al.
Publicado: (2008)

Pulmonary arterial hypertension associated with congenital heart disease: An omics study
por: Zhao, Maolin, et al.
Publicado: (2023)

Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease
por: van Dissel, Alexandra C., et al.
Publicado: (2018)

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics
por: Jin, Nan, et al.
Publicado: (2023)

Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension
por: Xu, Zhuoyuan, et al.
Publicado: (2021)

Efficacy of Inhaled Iloprost in Cor Pulmonale and Severe Pulmonary Hypertension Associated with Tuberculous Destroyed Lung
por: Park, Yae Min, et al.
Publicado: (2014)

Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease
por: Savale, Laurent, et al.
Publicado: (2019)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease
por: Arshad, Hassaan B., et al.
Publicado: (2021)

Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study
por: Huang, Li, et al.
Publicado: (2018)

Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases
por: Zhang, Xi, et al.
Publicado: (2016)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Acute Effects of Aerosolized Iloprost in COPD Related Pulmonary Hypertension - A Randomized Controlled Crossover Trial
por: Boeck, Lucas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3jg8vor4d2c61eodcm828lrtdg